Details of the Drug Reposition

General Information of This Drug (ID: DMDZ6Q3)

Drug Name
Napabucasin   DMDZ6Q3
Synonyms
83280-65-3; UNII-Z1HHM49K7O; 2-acetylnaphtho[2,3-b]furan-4,9-dione; Z1HHM49K7O; 2-Acetylnaphtho(2,3-b)furan-4,9-dione; 2-Acetyl-4H,9H-naphtho[2,3-b]furan-4,9-dione; Napabucasin [USAN:INN]; Napabucasin (BBI608); 2-Acetylfuranonaphthoquinone; CHEMBL64130; Napabucasin (JAN/USAN/INN); SCHEMBL1883845; Napabucasin - BBI 608/ FNQ; 2-Acetylfuro-1,4-naphthoquinone; DPHUWDIXHNQOSY-UHFFFAOYSA-N; MolPort-039-101-321; EX-A1314; ZINC13306865; s7977; AKOS027470201; DB12155; CS-1747; ACN-053294; HY-13919
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
3 Phase 3 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Solid tumour/cancer DISZR48F 2A00-2F9Z Phase 3 [1]
Colorectal cancer DISNH7P9 2B91.Z Phase 3 [2]
Pancreatic cancer DISJC981 2C10 Phase 3 [2]
------------------------------------------------------------------------------------
4 Phase 1/2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Recurrent glioblastoma DISHYPKS 2A00.00 Phase 1/2 [3]
Gastrointestinal cancer DISHIGUN 2C11 Phase 1/2 [2]
Hepatocellular carcinoma DIS0J828 2C12.02 Phase 1/2 [2]
Recurring respiratory infection DISG7AXL CA07-CA45 Phase 1/2 [2]
------------------------------------------------------------------------------------
1 Phase 1 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Haematological malignancy DISCDP7W 2B33.Y Phase 1 [2]
------------------------------------------------------------------------------------

References

1 First-in-Class Cancer Stemness Inhibitor Shows Promising Results in Advanced Colorectal Cancer. 2016 ASCO GI Conference. January 26, 2016.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)